Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer

Exclusion Criteria

• •1. Acute congestive heart failure, cardiomyopathy, or myocardial infarction as diagnosed by clinical, electrocardiogram or other means;
• •2. Rubber allergic people;
• •3. Patients who had received radiotherapy for bone lesions (patients who had received radiotherapy for lesions other than bone lesions could be enrolled 4 weeks later) ;
• •4. Have received a bone marrow or stem cell transplant;
• •5. Pregnant or lactating women;
• •6. Known to be seropositive for human immunodeficiency virus (HIV) or have AIDS;
• •7. Active tuberculosis disease; Or a recent history of contact with a person with TB, unless the tuberculin test is negative, Or tuberculosis patients undergoing treatment; Or a chest radiograph to check suspected cases;
• •8. Patients with alcohol or substance abuse, which affected their adherence to the study;以上
• •9. Known allergy to granulocyte colony-stimulating factors or excipients of drugs;
• •10. Received recombinant human granulocyte stimulating factor treatment within 6 weeks before inclusion;
• •11. Patients with a diagnosis of primary malignancy other than colorectal or pancreatic cancer were accompanied by the following, except: 1) malignancy in complete remission for at least 2 years prior to enrollment and without additional treatment during the study period; 2) non-melanoma skin cancer or malignant lentigo with adequate treatment and no evidence of disease recurrence; 3) Carcinoma in situ with adequate treatment and no evidence of disease recurrence;
• •12. Use of other investigational drugs within 1 month prior to study enrollment;
• •13. The investigators believe that the patients have diseases or symptoms that are not suitable for participation in the study and that the study drugs may harm the patient's health or affect the judgment of adverse events;